Pharmacokinetics of solifenacin in pediatric populations with overactive bladder or neurogenic detrusor overactivity
Abstract The aim of this investigation was to characterize and compare the pharmacokinetics (PK) of the antimuscarinic drug solifenacin in pediatric patients with overactive bladder (OAB) or neurogenic detrusor overactivity (NDO) utilizing data from three phase III trials. LION was a placebo‐control...
Saved in:
Main Authors: | Stacey Tannenbaum (Author), Martin den Adel (Author), Walter Krauwinkel (Author), John Meijer (Author), Adriana Hollestein‐Havelaar (Author), Frank Verheggen (Author), Donald Newgreen (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2020-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Oxybutynin and tolterodine for treatment of neurogenic detrusor overactivity: a pharmacoeconomic evaluation in the Brazilian context
by: Rodrigo Silva Suguino, et al.
Published: (2012) -
Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK
by: Zalmai Hakimi, et al.
Published: (2018) -
Regular and Irregular Use and Reasons for Discontinuation of Solifenacin Therapy in Patients with Overactive Bladder Managed by Urologists
by: Mateusz Małkowski, et al.
Published: (2024) -
Overactive bladder
by: Anna Zwierzyńska
Published: (2021) -
The Experimental overactive bladder modelling
by: O. I. Iatsyna, et al.
Published: (2018)